More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$4.87B
EPS
-0.99
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
0.693259
Previous close
$15.11
Today's open
$15.51
Day's range
$13.60 - $15.69
52 week range
$2.52 - $24.28
show more
CEO
Jonathan E. Lim
Employees
103
Headquarters
San Diego, CA
Exchange
Nasdaq Global Select
Shares outstanding
350956416
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat
ERAS-0015 will be evaluated with PRMT5 inhibitor navlimetostat in MTAP-deleted pancreatic cancer in Phase 1/2 trial
GlobeNewsWire • a day ago

Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise
SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it will host a virtual investor event on Friday, November 20, 2026, at 8:00 a.m. Eastern Time to discuss updated Phase 1 data for ERAS-0015, a potential best-in-class pan-RAS molecular glue for RAS-mutant solid tumors, and other updates.
GlobeNewsWire • Nov 16, 2026

Erasca Reports Third Quarter 2026 Business Updates and Financial Results
ERAS-0015 granted FDA Fast Track Designation for metastatic pancreatic adenocarcinoma; advancing toward three potentially registration-enabling trials in pancreatic and lung cancers Updated ERAS-0015 monotherapy and nonclinical ERAS-0015/ERAS-4001 combination data to be presented at ENA; expect preliminary ERAS-4001 data in H2 2026 and ERAS-0015 data in H1 2027 Cash, cash equivalents, and marketable securities of $948 million as of September 30, 2026 SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended September 30, 2026. “The emerging clinical profile of ERAS-0015 continues to support its potential as a foundational therapy across RAS-mutant cancers, both as a monotherapy and backbone for combination regimens,” said Jonathan E.
GlobeNewsWire • Nov 12, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PRNewsWire • Nov 12, 2026

Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
BOSTON and SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer and Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the Phase 1/2 study of oral PRMT5 inhibitor vopimetostat in combination with pan-RAS molecular glue ERAS-0015 in patients with MTAP-deleted pancreatic ductal adenocarcinoma (PDAC) and MTAP-deleted/RAS-mutant non-small cell lung cancer (NSCLC) is now open for enrollment. “The encouraging clinical activity, durability and tolerability observed to date with vopimetostat in combination with RAS inhibition reinforce our belief that co-targeting PRMT5 and RAS represents a promising new frontier in the treatment of pancreatic cancer and potentially other RAS-driven cancers,” said Malte Peters, M.D.
GlobeNewsWire • Nov 4, 2026

Erasca to Present at Upcoming Conferences in November
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in November 2026 and will also participate in one-on-one investor meetings at each of these conferences. Guggenheim 3 rd Annual Healthcare Innovation Conference Location: InterContinental Boston, Boston, MAFormat: Fireside Chat Date and Time: Tuesday, November 10, 3:30 pm Eastern Time Stifel 2026 Healthcare Conference Location: Lotte New York Palace, New York, NY Format: Fireside Chat Date and Time: Wednesday, November 11, 9:20 am Eastern Time Jefferies Global Healthcare Conference Location: The Waldorf Hilton, London, UK Format: Fireside Chat Date and Time: Wednesday, November 18, 12:30 pm Greenwich Mean Time A live audio webcast of the events will be available online at Erasca.com/events.
GlobeNewsWire • Nov 3, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Erasca, Inc. - ERAS
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
GlobeNewsWire • Oct 27, 2026

ERAS Investors with $100,000 in Losses Have Opportunity to Join Erasca, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $ERAS--ERAS Investors with $100,000 in Losses Have Opportunity to Join Erasca, Inc. Fraud Investigation with SBS Law.
Business Wire • Oct 23, 2026

Erasca: Revolution's Approval Just Took Risk Out Of The Fast Follower
Erasca (ERAS) is now a fully funded fast follower in RAS-targeted oncology, with ~$1B pro forma liquidity and three potential registration-enabling trials ahead. Daraxonrasib's FDA approval validates the RAS mechanism, shifting competition to tolerability and dose intensity, where ERAS-0015 shows potential differentiation. ERAS-0015 demonstrates strong tolerability, no dose-limiting toxicities, and high dose intensity, supporting its case for durable efficacy in key indications.
Seeking Alpha • Oct 5, 2026

ERASCA, INC. (NASDAQ: ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP , a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain directors and officers of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS).
GlobeNewsWire • Sep 22, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Erasca Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.